Sol-Gel Technologies Financials - Benzinga

Sol-Gel Technologies Ltd

SLGLNASDAQ

Trade with Public

Trade with Public

$77.39

-0.34-0.44%

At close: Aug 24, 5:00 PM EST

$77.73

0.340.44%

After Hours: 9:18 AM EST

Earnings: Q2 2026 Earnings were released on Thu Aug 20th, before the market open

Overview News Earnings Forecast Price TargetsFinancialsSentiment Ownership Compare Stock Report

Sol-Gel Technologies Financials

Sol-Gel Technologies (SLGL) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Sol-Gel Technologies Q2 EPS $(1.13) Beats $(2.31) Estimate, Sales $591.000K Beat $75.000K Estimate

Sol-Gel Technologies (NASDAQ:SLGL) reported quarterly losses of $(1.13) per share which beat the analyst consensus estimate of $(2.31) by 51.08 percent. This is a 127.1 percent decrease over earnings of $4.17 per share

Benzinga Newsdesk

PRO
Sol-Gel Technologies Q1 EPS $(1.31) Beats $(1.84) Estimate, Sales $108.000K Miss $900.000K Estimate

Sol-Gel Technologies (NASDAQ:SLGL) reported quarterly losses of $(1.31) per share which beat the analyst consensus estimate of $(1.84) by 28.8 percent. This is a 59.06 percent increase over losses of $(3.20) per share

Benzinga Newsdesk

PRO
Sol-Gel Technologies Q3 EPS $(2.13) Misses $(2.09) Estimate, Sales $400.000K Beat $300.000K Estimate

Sol-Gel Technologies (NASDAQ:SLGL) reported quarterly losses of $(2.13) per share which missed the analyst consensus estimate of $(2.09) by 1.91 percent. This is a 1538.46 percent decrease over losses of $(0.13) per

Benzinga Newsdesk

PRO
Sol-Gel Technologies Q2 EPS $4.17 Beats $(0.07) Estimate, Sales $17.261M Beat $2.900M Estimate

Sol-Gel Technologies (NASDAQ:SLGL) reported quarterly earnings of $4.17 per share which beat the analyst consensus estimate of $(0.07) by 6057.14 percent. This is a 495.71 percent increase over earnings of $0.70 per

Benzinga Newsdesk

PRO
Sol-Gel Technologies Q1 EPS $(3.20) Vs. (2.30) Prior Year, Sales $1.03M Miss $1.20M Estimate

Sol-Gel Technologies (NASDAQ:SLGL) reported quarterly losses of $(3.20) per share. This is a 39.13 percent decrease over losses of $(2.30) per share from the same period last year. The company reported quarterly sales of

Benzinga Newsdesk

Cue Biopharma, Inc. Reports Q2 Loss, Tops Revenue Estimates

Cue Biopharma, Inc. (NASDAQ: CUE) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to loss of $0.29 per share a year ago. These figures are adjusted for non-recurring items.

Zacks